MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) – Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncological and psychiatric disorders by modulating effects of the hormone cortisol, announced today that Amy Flood has joined the company as director of human resources and communications.
“I am very pleased to welcome Amy to our leadership team,” said Joseph K. Belanoff, MD, President and CEO of Corcept. “She has played a key role in building the talented teams that have made Gilead Sciences so successful. His proven communication skills and ability to attract, engage and retain talented employees will help us meet the challenges Corcept faces as we grow our business and grow our growing portfolio of selective cortisol modulators.
Ms. Flood has nearly 25 years of experience in team building and communications in the biotech industry. Previously, she spent 21 years at Gilead Sciences, most recently as Senior Vice President of Public Affairs, where she led a global team responsible for corporate branding, employee communications, product public relations. , advocacy and philanthropy. While at Gilead, she also led company-wide efforts to expand professional development opportunities for women, a focused mentoring and team development initiative and multiple diversity-focused programs. , equity and inclusion. Prior to joining Gilead, Amy worked in health public relations in New York City, before moving to San Francisco in 1998 to help establish her company’s West Coast operations.
About Corcept Therapeutics
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncological and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the United States Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company has extensive intellectual property in the United States and abroad covering the makeup of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.